CO5590940A2 - Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo - Google Patents
Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceoInfo
- Publication number
- CO5590940A2 CO5590940A2 CO04053708A CO04053708A CO5590940A2 CO 5590940 A2 CO5590940 A2 CO 5590940A2 CO 04053708 A CO04053708 A CO 04053708A CO 04053708 A CO04053708 A CO 04053708A CO 5590940 A2 CO5590940 A2 CO 5590940A2
- Authority
- CO
- Colombia
- Prior art keywords
- opioid analgesic
- endothelin antagonist
- administered
- hydrochloride
- morphine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000000202 analgesic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000014 opioid analgesic Substances 0.000 abstract 10
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 7
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 2
- 239000008896 Opium Substances 0.000 abstract 2
- 229960004126 codeine Drugs 0.000 abstract 2
- 229960002069 diamorphine Drugs 0.000 abstract 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 229960001027 opium Drugs 0.000 abstract 2
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 abstract 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 abstract 1
- SVTKSKRNLMAUKF-HAIKCVHQSA-N (4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O SVTKSKRNLMAUKF-HAIKCVHQSA-N 0.000 abstract 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 abstract 1
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 abstract 1
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 abstract 1
- BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 229960004415 codeine phosphate Drugs 0.000 abstract 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 abstract 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 abstract 1
- 229960004193 dextropropoxyphene Drugs 0.000 abstract 1
- 229960002428 fentanyl Drugs 0.000 abstract 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002764 hydrocodone bitartrate Drugs 0.000 abstract 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 abstract 1
- 229960001410 hydromorphone Drugs 0.000 abstract 1
- 229960002738 hydromorphone hydrochloride Drugs 0.000 abstract 1
- RWTWIZDKEIWLKQ-IWWMGODWSA-N levorphan tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 RWTWIZDKEIWLKQ-IWWMGODWSA-N 0.000 abstract 1
- 229960005157 levorphanol tartrate Drugs 0.000 abstract 1
- -1 methodone Chemical compound 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229960005195 morphine hydrochloride Drugs 0.000 abstract 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 abstract 1
- 229960004715 morphine sulfate Drugs 0.000 abstract 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 abstract 1
- 229960003066 morphine tartrate Drugs 0.000 abstract 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 abstract 1
- 229960005374 oxymorphone hydrochloride Drugs 0.000 abstract 1
- 229960000482 pethidine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1.- Un método para tratar o evitar el dolor que comprende administrar a un mamífero en necesidad de lo mismo una cantidad terapéuticamente efectiva de (a) un analgésico opiáceo y (b) una cantidad terapéuticamente efectiva de un antagonista de endotelina.2.- El método de la reivindicación 1, en el cual el analgésico opiáceo y el antagonista de endotelina se administran en forma simultánea.3.- El método de la reivindicación 2, en el cual el analgésico opiáceo y el antagonista de endotelina se administran a partir de una composición individual.4.- El método de la reivindicación 2, en el cual el analgésico opiáceo y el antagonista de endotelina se administran a partir de composiciones separadas.5.- El método de la reivindicación 1, en el cual el analgésico opiáceo y el antagonista de endotelina se administran en forma secuencial.6.- El método de la reivindicación 5, en el cual el analgésico opiáceo se administra antes del antagonista de endotelina.7.- El método de la reivindicación 5, en el cual el antagonista de endotelina se administra antes del analgésico opiáceo.8.- El método de la reivindicación 1, en el cual el analgésico opiáceo se selecciona del grupo que consiste de un alcaloide del opio, un analgésico opiáceo semi-sintético, y una mezcla de los mismos.9.- El método de la reivindicación 1, en el cual el analgésico opiáceo se selecciona del grupo que consiste de opio, morfina, sulfato de morfina, codeína, fosfato de codeína, sulfato de codeína, diacetilmorfina, clorhidrato de morfina, tartrato de morfina, clorhidrato de diacetilmorfina; bromhidrato de dextrometorfan, bitartrato de hidrocodona, hidromorfona, clorhidrato de hidromorfona, tartrato de levorfanol, clorhidrato de oximorfona, clorhidrato de oxicodona, fentanil, meperidina, metodona, propoxifeno, y mezclas de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33359901P | 2001-11-27 | 2001-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5590940A2 true CO5590940A2 (es) | 2005-12-30 |
Family
ID=23303472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04053708A CO5590940A2 (es) | 2001-11-27 | 2004-06-08 | Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7973064B2 (es) |
| EP (1) | EP1448233A2 (es) |
| JP (1) | JP2005513033A (es) |
| CN (1) | CN1646166A (es) |
| AU (1) | AU2002348224A1 (es) |
| BR (1) | BR0214481A (es) |
| CA (1) | CA2464768C (es) |
| CO (1) | CO5590940A2 (es) |
| EA (1) | EA200400734A1 (es) |
| EC (1) | ECSP045153A (es) |
| MX (1) | MXPA04005003A (es) |
| NO (1) | NO20042612L (es) |
| WO (1) | WO2003045434A2 (es) |
| ZA (1) | ZA200403162B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070300258A1 (en) * | 2001-01-29 | 2007-12-27 | O'connor Daniel | Methods and systems for providing media assets over a network |
| DK1395289T3 (da) * | 2001-06-07 | 2011-03-28 | Christine Dr Sang | Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist |
| TWI232102B (en) * | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
| DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| ES2384208T3 (es) | 2001-11-01 | 2012-07-02 | Spectrum Pharmaceuticals, Inc. | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. |
| US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
| US7351692B2 (en) * | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| US20040138121A1 (en) | 2002-10-24 | 2004-07-15 | Anil Gulati | Method and composition for preventing and treating solid tumors |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8217010B2 (en) | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| US20090221490A1 (en) * | 2005-09-09 | 2009-09-03 | Anil Gulati | Endothelin Receptors In Morphine Withdrawal |
| CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CN101534852B (zh) | 2006-08-31 | 2013-02-13 | 光谱医药公司 | 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化 |
| GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
| WO2009015917A2 (en) * | 2007-05-14 | 2009-02-05 | F. Hoffmann-La Roche Ag | Dihydroquinone and dihydronaphthridine inhibitors of jnk |
| US20090143426A1 (en) * | 2007-12-04 | 2009-06-04 | Ralph Anthony Stephani | Synthesis of 1,3,6-trisubstituted-2-carboxyquinol-4-ones as selective ET A antagonists and their use as medicaments |
| PL2424529T3 (pl) * | 2009-04-30 | 2017-06-30 | Midwestern University | Nowe postępowania terapeutyczne z zastosowaniem centakwiny |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| ES2825101T3 (es) | 2013-07-08 | 2021-05-14 | Univ Midwestern | Composiciones y métodos para el tratamiento de trastornos neuropsiquiátricos usando un agonista del receptor de la endotelina B |
| CN112569238A (zh) * | 2019-09-30 | 2021-03-30 | 武汉大学 | 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| JPH08139146A (ja) | 1994-11-14 | 1996-05-31 | Shin Etsu Handotai Co Ltd | 半導体表面のライフタイム評価方法 |
| MX9703988A (es) | 1994-12-12 | 1998-02-28 | Omeros Med Sys Inc | SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO. |
| US6673832B1 (en) * | 1998-05-04 | 2004-01-06 | Gudarz Davar | Methods for identifying compounds for treating pain |
| CA2409927A1 (en) | 2000-05-31 | 2001-12-06 | Warner-Lambert Company | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| AU2002241736A1 (en) * | 2000-12-21 | 2002-07-01 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030232787A1 (en) * | 2001-05-08 | 2003-12-18 | Dooley David James | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
-
2002
- 2002-11-21 US US10/301,449 patent/US7973064B2/en not_active Expired - Fee Related
- 2002-11-22 CA CA002464768A patent/CA2464768C/en not_active Expired - Fee Related
- 2002-11-22 WO PCT/US2002/037461 patent/WO2003045434A2/en active Application Filing
- 2002-11-22 EP EP02782353A patent/EP1448233A2/en not_active Ceased
- 2002-11-22 JP JP2003546935A patent/JP2005513033A/ja active Pending
- 2002-11-22 CN CNA028235703A patent/CN1646166A/zh active Pending
- 2002-11-22 MX MXPA04005003A patent/MXPA04005003A/es not_active Application Discontinuation
- 2002-11-22 BR BR0214481-6A patent/BR0214481A/pt not_active IP Right Cessation
- 2002-11-22 AU AU2002348224A patent/AU2002348224A1/en not_active Abandoned
- 2002-11-22 EA EA200400734A patent/EA200400734A1/ru unknown
-
2004
- 2004-04-26 ZA ZA200403162A patent/ZA200403162B/en unknown
- 2004-06-08 CO CO04053708A patent/CO5590940A2/es not_active Application Discontinuation
- 2004-06-15 EC EC2004005153A patent/ECSP045153A/es unknown
- 2004-06-22 NO NO20042612A patent/NO20042612L/no not_active Application Discontinuation
-
2009
- 2009-11-03 US US12/611,307 patent/US8114896B2/en not_active Expired - Fee Related
-
2010
- 2010-08-02 US US12/848,378 patent/US8410148B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7973064B2 (en) | 2011-07-05 |
| EP1448233A2 (en) | 2004-08-25 |
| CA2464768C (en) | 2009-12-29 |
| CA2464768A1 (en) | 2003-06-05 |
| MXPA04005003A (es) | 2004-08-11 |
| US20100311665A1 (en) | 2010-12-09 |
| US20030100507A1 (en) | 2003-05-29 |
| ZA200403162B (en) | 2005-01-26 |
| JP2005513033A (ja) | 2005-05-12 |
| EA200400734A1 (ru) | 2004-12-30 |
| BR0214481A (pt) | 2004-09-14 |
| NO20042612L (no) | 2004-06-22 |
| WO2003045434A3 (en) | 2003-09-25 |
| WO2003045434A2 (en) | 2003-06-05 |
| US8114896B2 (en) | 2012-02-14 |
| US20100113396A1 (en) | 2010-05-06 |
| CN1646166A (zh) | 2005-07-27 |
| AU2002348224A1 (en) | 2003-06-10 |
| ECSP045153A (es) | 2004-08-27 |
| US8410148B2 (en) | 2013-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5590940A2 (es) | Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo | |
| RU2009125597A (ru) | Пролекарства и способы их получения и применения | |
| US20210196706A1 (en) | Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response | |
| AR042463A1 (es) | Tratamiento del dolor con combinaciones de nalbufina y agonistas del receptor de opioides kappa y antagosnistas del receptor opioides | |
| JP2003528819A5 (es) | ||
| JP2011519930A5 (es) | ||
| JP2015514743A5 (es) | ||
| RU2012124063A (ru) | Лекарственная комбинация с теобромином и ее использование в лечении | |
| US10226457B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| JP2007503473A5 (es) | ||
| SOUDANI et al. | Therapeutic and Toxic Effects of Alkaloids Extracted of Somnniferum Papaver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |